公开(公告)号：US20200030260A1

公开(公告)日：2020-01-30

申请号：US16523568

申请日：2019-07-26

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Robin Paul Sherrington ,  Jean-Jacques Alexandre Cadieux ,  Parisa Karimi Tari ,  Jeffrey Paul Bechard

IPC: A61K31/137 ,  A61K31/24 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.